Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-month subcutaneous DMPA contraception study
ISRCTN62695528Phase 3Completed
- Sponsor
- FHI 360
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of medroxyprogesterone acetate in contraception (2 arms), sponsored by FHI 360. Primary endpoint: Pregnancy occurrence. Started Jul 2022; status: completed.
02
Drugs
medroxyprogesterone acetate
03
Conditions
contraception
Beyond the preview
Go deeper on ISRCTN62695528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62695528.